News

Further research is needed to devise strategies for the prevention and treatment of asthma attacks.

Dr. Leng discusses the progression of dry AMD patients in the IRIS registry from early stages to potential GA, as well as the benefit in narrowing the clinical definition of intermediate dry AMD.

At AAO 2021, Dr. Sahel discussed the findings of the PIONEER trial on the combination of an optogenetics device and gene therapy in treatment of RP.

Earlier today the FDA authorized booster doses for the Pfizer or Moderna vaccine for all adults.

The agent is the first therapeutic treatment indicated to increase linear growth in pediatric patients with achondroplasia with open epiphyses.

In a study presented at ACG, investigators focus on quality of life improvements for patients with irritable bowel syndrome.

The biologic has shown promise in the management of both plaque psoriasis and psoriatic arthritis.

Dr. Fasipe shares about her experience at the National Organization for Rare Disease Summit 2021 as the opening plenary speaker.

Dr. Worobey suggested in his report that the vendor’s ties to the Huanan Seafood Wholesale Market strongly suggested the pandemic originated at the Wuhan market.

Investigators also noted that higher rates of infection were observed in Black patients.

More than 90% of patients in hypertension and lipid management accomplished their predetermined goals after completing the remote program.

Investigators called for prospective studies with longer time horizons to see if these associations persist throughout childhood.

To the investigators’ knowledge, the study offers insights into lesion presentations on undiagnosed adults with vitiligo.

Investigators recommended the development and validation of a screening tool for FAA that transcends the current food allergy-specific measures.

Investigators found that using virtual reality to reduce pain levels during operational hsyteroscopy was not effective.

Dr. Avery discusses the positive results of RGX-314 gene therapy, noting dramatic reduction in need for therapy, with stable vision and good thickness results

After 1 year, 37% of patients had died and 65% of patients were readmitted to the hospital.

Bentracimab achieved the predetermined primary endpoint of immediate and sustained reversal of the antiplatelet effects of ticagrelor in the REVERSE-IT trial.

Despite this, asthma severity was not associated with higher risk of COVID-19.

Young smokers in 2017 were more likely to have other comorbid conditions including hypertension, diabetes, and obesity.

A new study from the American Heart Association Scientific Sessions 2021 found that atherosclerotic cardiovascular disease risk increases with sdLDL-C levels, regardless of sex or race.

Dr. Dhoot discusses data on visual acuity from the phase 3 KESTREL and KITE trials, comparing brolucizumab to aflibercept at 52 weeks.

Investigators said that patient-reported outcomes from the 2 abrocitinib groups showed greater efficacy than the dupilumab and placebo groups.

Hydroxyurea has been on the market for decades and yet it's underutilized as a treatment for sickle cell disease.

EaseVRx utilizes cognitive behavioral therapy and other behavioral therapy techniques.

There was a 135% reduction in platelet inhibition observed within 5-10 minutes following bentracimab infusion.

The Director of Retina Services at Wills Eye Hospital joins to discuss the historic FDA approval granted for a novel method of ophthalmic care: a permanent implant that allows for vision-saving formula therapy to treat the eye continually.

Dr. Khanani highlights data from MERLIN showing noninferiority of brolucizumab to aflibercept in nAMD treatment, but a higher rate of intraocular inflammation.

Treatment with statins, nitrates, dihydropyridines, verapamil, and proton-pump inhibitors were predictors of death or ischemic events for patients in the HGFR group.

Dr. Sheth discusses the data from the late-breaking Phase 2B ALTISSIMO study.